Halozyme Touts $1.8B Revenue Outlook, Expanding Subcutaneous Drug Delivery

Biopharmaceutical company highlights growth from ENHANZE royalties and new collaboration deals at industry conference.

Mar. 21, 2026 at 8:19am

Got story updates? Submit your updates here. ›

Halozyme Therapeutics executives provided an upbeat outlook for the company's royalty-driven growth, forecasting $1.7 billion to $1.8 billion in total revenue for the current year, driven by strong performance of key partnered products enabled by its ENHANZE subcutaneous drug delivery platform. The company highlighted robust adoption of ENHANZE-enabled products like Perjeta, VYVGART, and OCREVUS, and expects a wave of newer launches to drive further expansion.

Why it matters

Halozyme's ENHANZE technology is enabling a shift toward more convenient subcutaneous administration for a range of biologic therapies, which can improve patient experience and expand access. As the company's royalty revenue grows, it underscores the value of its platform in broadening the addressable market for its partners' products.

The details

Halozyme CEO Helen Torley reiterated the company's 2023 revenue guidance of $1.7 billion to $1.8 billion, representing 22% to 30% year-over-year growth. Royalties from ENHANZE-enabled products are expected to reach $1.1 billion to $1.2 billion, growing 30% to 35%. Key contributors include Perjeta, VYVGART, and OCREVUS, which have seen robust subcutaneous adoption. Torley also highlighted emerging opportunities from newer launches like Opdivo, OCREVUS, RYBREVANT, and Tecentriq subcutaneous formulations. Additionally, Halozyme signed three new ENHANZE deals in late 2025 and expects at least three more in 2026, while also advancing its Hypercon subcutaneous delivery technology.

  • Halozyme provided its 2023 revenue guidance in March 2026.
  • The company expects to meet with a U.S. judge in June 2026 regarding ongoing litigation with Merck.
  • Halozyme expects 1-2 new Hypercon deals in 2026.
  • Halozyme expects 6 new ENHANZE Phase 1 starts and 2 new Hypercon starts in 2023.

The players

Halozyme Therapeutics

A biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies, including its flagship ENHANZE platform.

Helen Torley

The CEO of Halozyme Therapeutics.

Roche

A pharmaceutical company that markets the subcutaneous formulations of Perjeta and OCREVUS, which utilize Halozyme's ENHANZE technology.

argenx

A biopharmaceutical company that markets the subcutaneous formulation of VYVGART, which utilizes Halozyme's ENHANZE technology.

Johnson & Johnson

A pharmaceutical company that markets the subcutaneous formulation of RYBREVANT, which utilizes Halozyme's ENHANZE technology.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Halozyme's growth story is driven by the expanding adoption of its ENHANZE subcutaneous drug delivery platform, which is enabling more convenient administration and broader access to a range of biologic therapies. The company's royalty-based model and pipeline of new ENHANZE and Hypercon deals position it for continued expansion in the years ahead.